BE897535A - Medicament a action cytostatique - Google Patents

Medicament a action cytostatique Download PDF

Info

Publication number: BE897535A
Authority: BE; Belgium
Prior art keywords: fatty acids; esters; content; medicament; acid
Prior art date: 1982-08-12

Application number

BE0/211357A

Other languages

English (en)

French (fr)

Original Assignee

Schulze Heinrich Erichsen Frie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-08-12

Filing date

1983-08-12

Publication date

1983-12-01

1983-08-12 Application filed by Schulze Heinrich Erichsen Frie filed Critical Schulze Heinrich Erichsen Frie

1983-12-01 Publication of BE897535A publication Critical patent/BE897535A/fr

Links

239000003814 drug Substances 0.000 title claims description 10
230000001085 cytostatic effect Effects 0.000 title claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 12
229930195729 fatty acid Natural products 0.000 claims description 12
239000000194 fatty acid Substances 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 10
150000004665 fatty acids Chemical class 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 3
UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims description 2
WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical class CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims description 2
150000001656 butanoic acid esters Chemical class 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 description 18
210000004027 cell Anatomy 0.000 description 13
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 11
201000011510 cancer Diseases 0.000 description 10
230000004060 metabolic process Effects 0.000 description 7
239000002253 acid Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000009471 action Effects 0.000 description 4
230000034659 glycolysis Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
-1 alkali metal salts Chemical class 0.000 description 3
150000001735 carboxylic acids Chemical class 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000006378 damage Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
230000012010 growth Effects 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
150000004666 short chain fatty acids Chemical class 0.000 description 2
235000021391 short chain fatty acids Nutrition 0.000 description 2
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003925 fat Substances 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000002361 ketogenic effect Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229950006238 nadide Drugs 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin

Landscapes

Health & Medical Sciences (AREA)
Emergency Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BE0/211357A 1982-08-12 1983-08-12 Medicament a action cytostatique BE897535A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19823229956 DE3229956A1 (de)	1982-08-12	1982-08-12	Arzneimittel mit cytostatischer wirkung

Publications (1)

Publication Number	Publication Date
BE897535A true BE897535A (fr)	1983-12-01

Family

ID=6170656

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE0/211357A BE897535A (fr)	1982-08-12	1983-08-12	Medicament a action cytostatique

Country Status (6)

Country	Link
BE (1)	BE897535A (de)
DE (1)	DE3229956A1 (de)
FR (1)	FR2531632A1 (de)
LU (1)	LU84951A1 (de)
NL (1)	NL8302829A (de)
SE (1)	SE8304332L (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2633929B2 (fr) *	1987-09-25	1995-05-24	Picardie Universite	Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
HU209973B (en) *	1988-03-09	1995-01-30	Biorex Kutato Fejlesztoe Kft	Process for production of antiviral and immunstimular pharmaceutical composition
JPH01299222A (ja) *	1988-05-26	1989-12-04	Otsuka Pharmaceut Factory Inc	抗腫瘍剤
FR2723096B1 (fr) *	1994-07-28	1996-10-18	Univ Picardie	Esters associant les acides phenylacetique,3-phenyl-propionique, 4-phenyl-butyrique et n-butyrique au d-mannose, au xylitol et a leurs derives. applications comme medicaments
US8105809B2 (en)	2008-07-03	2012-01-31	Accera, Inc.	Enzymatic synthesis of acetoacetate esters and derivatives
WO2018187852A1 (en) *	2017-04-12	2018-10-18	Cavaleri Franco	Butyrate and beta-hydroxybutyrate compositions and methods of use thereof

1982
- 1982-08-12 DE DE19823229956 patent/DE3229956A1/de not_active Withdrawn
1983
- 1983-08-04 LU LU84951A patent/LU84951A1/de unknown
- 1983-08-09 SE SE8304332A patent/SE8304332L/ not_active Application Discontinuation
- 1983-08-11 NL NL8302829A patent/NL8302829A/nl not_active Application Discontinuation
- 1983-08-11 FR FR8313233A patent/FR2531632A1/fr active Granted
- 1983-08-12 BE BE0/211357A patent/BE897535A/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE3229956A1 (de)	1984-02-16
FR2531632B3 (de)	1985-03-08
NL8302829A (nl)	1984-03-01
LU84951A1 (de)	1983-12-28
SE8304332L (sv)	1984-02-13
FR2531632A1 (fr)	1984-02-17
SE8304332D0 (sv)	1983-08-09

Legal Events

Date

Code

Title

Description

1985-02-28

RE

Patent lapsed

Owner name: SCHULZE HEINRICH, ERICHSEN FRIEDRICH K., FISCHE

Effective date: 19840812

Publication	Publication Date	Title
Opie et al.	1979	Adrenaline-induced “oxygen-wastage” and enzyme release from working rat heart. Effects of calcium antagonism, β-blockade, nicotinic acid and coronary artery ligation
BE1001209A3 (fr)	1989-08-22	Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
AU652992B2 (en)	1994-09-15	Method and composition for treating reperfusion injury
EP1458371A1 (de)	2004-09-22	Pyruvathaltige kardioplegielösungen zur verabreichung an das herz während einem chirurgischen herz-lungen eingriff, sowie verfahren zu ihrer verwendung
JP2000344602A (ja)	2000-12-12	動物の細胞または臓器の保存剤およびその保存方法。
GB2126082A (en)	1984-03-21	Pharmaceutical preparations having analgetic and cytostatic activity
Alva et al.	2016	Fructose 1, 6-bisphosphate: A summary of its cytoprotective mechanism
Kretschmer et al.	1978	Autotransplantation of pancreatic fragments to the portal vein and spleen of totally pancreatectomized dogs: a comparative evaluation
Thornell et al.	1979	Inhibition of prostaglandin synthesis as a treatment for biliary pain
EP1283708A2 (de)	2003-02-19	Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
CN109287622A (zh)	2019-02-01	一种骨髓回输治疗伴hiv感染的结直肠癌和失代偿肝硬化合并小肝癌用的组织保存液
Rossini	1976	Why control blood glucose levels?
EP0614366B1 (de)	1996-09-11	Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
EP1432414B1 (de)	2006-08-23	Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
US9237744B2 (en)	2016-01-19	Preservative solution for cells, tissues and organs containing rare sugar and preservative method thereof
FR2531632A1 (fr)	1984-02-17	Produits pharmaceutiques avec action cytostatique, a base d'esters d'acides gras
CN1568929A (zh)	2005-01-26	含有腐植酸的化妆品及腐植酸在化妆品方面的应用
FR2634125A1 (fr)	1990-01-19	Composition pharmaceutique a base de superoxyde dismutase
BE1005623A3 (fr)	1993-11-23	Composition pour accelerer la guerison des blessures.
CN115252898B (zh)	2023-08-18	一种长效微粒ⅰ型与ⅴ型胶原蛋白复合植入剂
JPH02191212A (ja)	1990-07-27	３―ヒドロキシ酪酸（β―ヒドロキシ酪酸）及びその塩からなる輸液製剤
CA2493074A1 (fr)	2004-02-05	Elevation du taux d'heme oxygenase avec des derives de la rheine
Roch‐Norlund et al.	1972	Metabolism of fructose in diabetes
FR2542999A1 (fr)	1984-09-28	Procede de fabrication de liposome contenant un ou plusieurs sterylglucosides et monopalmitates de sterylglucosides et nouveaux produits ainsi obtenus
FR2635462A1 (fr)	1990-02-23	Preparation medicamenteuse a base d'extrait d'ortie urtica kiovensis (rogiwicz), leur utilisation pour le traitement de tumeurs, et procedes de fabrication